FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896001331> ?p ?o ?g. }

• W2896001331 endingPage "3484" @default.
• W2896001331 startingPage "3477" @default.
• W2896001331 abstract "Purpose BRAF V600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of BRAF V600 , in patients with gliomas that harbor this mutation. Patients and Methods The VE-BASKET study was an open-label, nonrandomized, multicohort study for BRAF V600 -mutant nonmelanoma cancers. Patients with BRAF V600 -mutant glioma received vemurafenib 960 mg twice per day continuously until disease progression, withdrawal, or intolerable adverse effects. Key end points included confirmed objective response rate by RECIST version 1.1, progression-free survival, overall survival, and safety. Results Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including malignant diffuse glioma (n = 11; six glioblastoma and five anaplastic astrocytoma), PXA (n = 7), anaplastic ganglioglioma (n = 3), pilocytic astrocytoma (n = 2), and high-grade glioma, not otherwise specified (n = 1), were treated. Confirmed objective response rate was 25% (95% CI, 10% to 47%) and median progression-free survival was 5.5 months (95% CI, 3.7 to 9.6 months). In malignant diffuse glioma, best response included one partial response and five patients with stable disease, two of whom had disease stabilization that lasted more than 1 year. In PXA, best response included one complete response, two partial responses, and three patients with stable disease. Additional partial responses were observed in patients with pilocytic astrocytoma and anaplastic ganglioglioma (one each). The safety profile of vemurafenib was generally consistent with that of previously published studies. Conclusion Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAF V600 -mutant gliomas, although efficacy seemed to vary qualitatively by histologic subtype. Additional study is needed to determine the optimal use of vemurafenib in patients with primary brain tumors and to identify the mechanisms driving differential responses across histologic subsets." @default.
• W2896001331 created "2018-10-26" @default.
• W2896001331 creator A5004300577 @default.
• W2896001331 creator A5004573264 @default.
• W2896001331 creator A5021287587 @default.
• W2896001331 creator A5025120810 @default.
• W2896001331 creator A5025511599 @default.
• W2896001331 creator A5039402966 @default.
• W2896001331 creator A5042155392 @default.
• W2896001331 creator A5042461515 @default.
• W2896001331 creator A5043322435 @default.
• W2896001331 creator A5043675371 @default.
• W2896001331 creator A5045084904 @default.
• W2896001331 creator A5049243227 @default.
• W2896001331 creator A5055583780 @default.
• W2896001331 creator A5061424072 @default.
• W2896001331 creator A5064343766 @default.
• W2896001331 creator A5068193017 @default.
• W2896001331 creator A5068792374 @default.
• W2896001331 creator A5068953785 @default.
• W2896001331 creator A5076690638 @default.
• W2896001331 creator A5086593040 @default.
• W2896001331 creator A5087055974 @default.
• W2896001331 date "2018-12-10" @default.
• W2896001331 modified "2023-10-13" @default.
• W2896001331 title "BRAF Inhibition in <i>BRAF</i>^V600-Mutant Gliomas: Results From the VE-BASKET Study" @default.
• W2896001331 cites W1441792155 @default.
• W2896001331 cites W1812256879 @default.
• W2896001331 cites W1846586690 @default.
• W2896001331 cites W1858161324 @default.
• W2896001331 cites W1922733886 @default.
• W2896001331 cites W1965370740 @default.
• W2896001331 cites W1968287404 @default.
• W2896001331 cites W2010760434 @default.
• W2896001331 cites W2019607817 @default.
• W2896001331 cites W2045538453 @default.
• W2896001331 cites W2049839547 @default.
• W2896001331 cites W2078694254 @default.
• W2896001331 cites W2080541203 @default.
• W2896001331 cites W2092241508 @default.
• W2896001331 cites W2107224559 @default.
• W2896001331 cites W2109816625 @default.
• W2896001331 cites W2115078134 @default.
• W2896001331 cites W2124664680 @default.
• W2896001331 cites W2124736921 @default.
• W2896001331 cites W2127931233 @default.
• W2896001331 cites W2132697290 @default.
• W2896001331 cites W2146267855 @default.
• W2896001331 cites W2156330848 @default.
• W2896001331 cites W2158681922 @default.
• W2896001331 cites W2162643152 @default.
• W2896001331 cites W2169590480 @default.
• W2896001331 cites W2170367762 @default.
• W2896001331 cites W2205491921 @default.
• W2896001331 cites W2409383155 @default.
• W2896001331 cites W2491982852 @default.
• W2896001331 cites W2503674037 @default.
• W2896001331 cites W2586159641 @default.
• W2896001331 cites W2589558057 @default.
• W2896001331 cites W2607167117 @default.
• W2896001331 cites W2613362156 @default.
• W2896001331 cites W2626614537 @default.
• W2896001331 cites W2737907665 @default.
• W2896001331 cites W2764070931 @default.
• W2896001331 cites W2766581537 @default.
• W2896001331 cites W2768388636 @default.
• W2896001331 cites W2770975168 @default.
• W2896001331 cites W2781606447 @default.
• W2896001331 cites W3164126191 @default.
• W2896001331 doi "https://doi.org/10.1200/jco.2018.78.9990" @default.
• W2896001331 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6286161" @default.
• W2896001331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30351999" @default.
• W2896001331 hasPublicationYear "2018" @default.
• W2896001331 type Work @default.
• W2896001331 sameAs 2896001331 @default.
• W2896001331 citedByCount "218" @default.
• W2896001331 countsByYear W28960013312019 @default.
• W2896001331 countsByYear W28960013312020 @default.
• W2896001331 countsByYear W28960013312021 @default.
• W2896001331 countsByYear W28960013312022 @default.
• W2896001331 countsByYear W28960013312023 @default.
• W2896001331 crossrefType "journal-article" @default.
• W2896001331 hasAuthorship W2896001331A5004300577 @default.
• W2896001331 hasAuthorship W2896001331A5004573264 @default.
• W2896001331 hasAuthorship W2896001331A5021287587 @default.
• W2896001331 hasAuthorship W2896001331A5025120810 @default.
• W2896001331 hasAuthorship W2896001331A5025511599 @default.
• W2896001331 hasAuthorship W2896001331A5039402966 @default.
• W2896001331 hasAuthorship W2896001331A5042155392 @default.
• W2896001331 hasAuthorship W2896001331A5042461515 @default.
• W2896001331 hasAuthorship W2896001331A5043322435 @default.
• W2896001331 hasAuthorship W2896001331A5043675371 @default.
• W2896001331 hasAuthorship W2896001331A5045084904 @default.
• W2896001331 hasAuthorship W2896001331A5049243227 @default.
• W2896001331 hasAuthorship W2896001331A5055583780 @default.
• W2896001331 hasAuthorship W2896001331A5061424072 @default.
• W2896001331 hasAuthorship W2896001331A5064343766 @default.
• W2896001331 hasAuthorship W2896001331A5068193017 @default.

• next